| Page 39 | Cafepharma

You are here

Primary tabs

[release] Following approval in Sweden, Lobsor eyes US entry for new Lecigon treatment for Parkinson’s Disease

Post date: October 8, 2018 - 10:08am

Bacteriophage Company AmpliPhi Presents Positive Data on Expanded Access Program for Serious S. aureus Infections

Post date: October 8, 2018 - 9:49am

Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer

Post date: October 8, 2018 - 9:25am

Aytu Prices Upcoming Public Offering at 13.2 Million

Post date: October 5, 2018 - 10:24am

Amicus Announces Positive Results for AT-GAA in Pompe Disease

Post date: October 5, 2018 - 9:46am

EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder

Post date: October 5, 2018 - 9:18am

Microbiome Report for Week Ending 9/29/18

Post date: October 4, 2018 - 2:59pm

Vaxart Stock Soars on Oral Flu Vaccine Results

Post date: October 4, 2018 - 9:57am

Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors

Post date: October 4, 2018 - 9:28am

Ophthotech Completes Recruitment for Ph IIb Trial of Zimura for Geographic Atrophy Secondary to Dry AMD

Post date: October 4, 2018 - 9:17am

Pages